Rindopepimut联合替莫唑胺治疗新诊断EGFRvIII表达胶质母细胞瘤(ACT IV):一项随机双盲国际3期试验
ACT IV研究在22国165家医院纳入745例新诊断EGFRvIII阳性胶质母细胞瘤患者,随机接受Rindopepimut或对照联合标准替莫唑胺化疗。预设中期分析因无效提前终止;微小残留病灶患者中位总生存Rindopepimut组20.1个月 vs 对照组20.0个月(HR 1.01,95%CI 0.79-1.30;p=0.93),无显著差异。
要点
- Rindopepimut联合替莫唑胺未改善新诊断EGFRvIII阳性胶质母细胞瘤患者的总生存。
- 微小残留病灶患者中位总生存Rindopepimut组20.1个月 vs 对照组20.0个月,无显著差异。
- 研究因预设中期分析显示无效而提前终止。
核心结论
- Rindopepimut未增加新诊断胶质母细胞瘤患者的生存。
- 作者认为可能需要包含Rindopepimut的联合方案才能显示免疫治疗在胶质母细胞瘤中的疗效。
研究设计与样本
- 随机、双盲、国际3期试验,从22个国家165家医院招募18岁及以上新诊断胶质母细胞瘤患者。
- 患者经中心分析确认表达EGFRvIII,接受最大程度手术切除并完成标准放化疗且无进展。
- 按1:1随机分配接受Rindopepimut(500 μg与150 μg GM-CSF混合)或对照(100 μg keyhole limpet haemocyanin)每月皮内注射直至进展或不耐受,同时联合标准口服替莫唑胺(150-200 mg/m2,每28天用5天)6-12周期或更长。
- 共入组745例患者(微小残留病灶405例,显著残留病灶338例,2例不可评估),随机分配至Rindopepimut联合替莫唑胺组(n=371)或对照联合替莫唑胺组(n=374)。
- 主要终点为微小残留病灶患者(放化疗后经中心审查强化肿瘤<2 cm2)的总生存,按改良意向治疗分析。
主要发现
- 研究在预设中期分析后因无效终止。
- 最终分析时,微小残留病灶患者中位总生存Rindopepimut组为20.1个月(95%CI 18.5-22.1),对照组为20.0个月(95%CI 18.1-21.9),无显著差异(HR 1.01,95%CI 0.79-1.30;p=0.93)。
- Rindopepimut组369例可治疗患者与对照组372例可治疗患者最常见的3-4级不良事件:血小板减少症(32例[9%] vs 23例[6%])、疲乏(6例[2%] vs 19例[5%])、脑水肿(8例[2%] vs 11例[3%])、癫痫发作(9例[2%] vs 8例[2%])、头痛(6例[2%] vs 10例[3%])。
- 严重不良事件包括癫痫发作(18例[5%] vs 22例[6%])和脑水肿(7例[2%] vs 12例[3%])。
- 研究中共16例死亡由不良事件导致(Rindopepimut组9例[4%],对照组7例[3%]),其中1例(64岁男性治疗11个月后肺栓塞)被评估为可能与Rindopepimut相关。
关键数值与推荐
- 微小残留病灶患者中位总生存:Rindopepimut组20.1个月(95%CI 18.5-22.1) vs 对照组20.0个月(95%CI 18.1-21.9),HR 1.01(95%CI 0.79-1.30),p=0.93。
- Rindopepimut组369例可治疗患者中3-4级血小板减少症32例(9%),对照组372例中23例(6%)。
- Rindopepimut组3-4级疲乏6例(2%),对照组19例(5%)。
- Rindopepimut组严重不良事件癫痫发作18例(5%),对照组22例(6%);脑水肿7例(2%) vs 12例(3%)。
局限性
- 研究在预设中期分析后因无效而终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in patients with EGFRvIII-positive glioblastoma. METHODS: In this randomised, double-blind, phase 3 trial, we recruited patients aged 18 years and older with glioblastoma from 165 hospitals in 22 countries. Eligible patients had newly diagnosed glioblastoma confirmed to express EGFRvIII by central analysis, and had undergone maximal surgical resection and completion of standard chemoradiation without progression. Patients were stratified by European Organisation for Research and Treatment of Cancer recursive partitioning analysis class, MGMT promoter methylation, and geographical region, and randomly assigned (1:1) with a prespecified randomisation sequence (block size of four) to receive rindopepimut (500 μg admixed with 150 μg GM-CSF) or control (100 μg keyhole limpet haemocyanin) via monthly intradermal injection until progression or intolerance, concurrent with standard oral temozolomide (150-200 mg/m2 for 5 of 28 days) for 6-12 cycles or longer. Patients, investigators, and the trial funder were masked to treatment allocation. The primary endpoint was overall survival in patients with minimal residual disease (MRD; enhancing tumour <2 cm2 post-chemoradiation by central review), analysed by modified intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01480479. FINDINGS: Between April 12, 2012, and Dec 15, 2014, 745 patients were enrolled (405 with MRD, 338 with significant residual disease [SRD], and two unevaluable) and randomly assigned to rindopepimut and temozolomide (n=371) or control and temozolomide (n=374). The study was terminated for futility after a preplanned interim analysis. At final analysis, there was no significant difference in overall survival for patients with MRD: median overall survival was 20·1 months (95% CI 18·5-22·1) in the rindopepimut group versus 20·0 months (18·1-21·9) in the control group (HR 1·01, 95% CI 0·79-1·30; p=0·93). The most common grade 3-4 adverse events for all 369 treated patients in the rindopepimut group versus 372 treated patients in the control group were: thrombocytopenia (32 [9%] vs 23 [6%]), fatigue (six [2%] vs 19 [5%]), brain oedema (eight [2%] vs 11 [3%]), seizure (nine [2%] vs eight [2%]), and headache (six [2%] vs ten [3%]). Serious adverse events included seizure (18 [5%] vs 22 [6%]) and brain oedema (seven [2%] vs 12 [3%]). 16 deaths in the study were caused by adverse events (nine [4%] in the rindopepimut group and seven [3%] in the control group), of which one-a pulmonary embolism in a 64-year-old male patient after 11 months of treatment-was assessed as potentially related to rindopepimut. INTERPRETATION: Rindopepimut did not increase survival in patients with newly diagnosed glioblastoma. Combination approaches potentially including rindopepimut might be required to show efficacy of immunotherapy in glioblastoma. FUNDING: Celldex Therapeutics, Inc.
引用
- Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017. PMID: 28844499. doi:10.1016/S1470-2045(17)30517-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。